Drug-Drug Interactions in HIV/HCV Coinfection

Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.

HCV Racial Disparities and Treatment Outcomes

Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients.

Preventing HCV With Needle/Syringe Programs

Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject ...

Short-Duration Treatment Regimens for HCV

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved ...

Treatment Challenges for Genotype 3 HCV

Data have shown patients with genotype 3 HCV have faster progression of fibrosis and higher rates of cirrhosis, severe steatosis, and hepatocellular carcinoma.

Hepatocellular Carcinoma: Treatment Challenges

Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are ...

Hepatitis B: Current State of Affairs

One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access ...

Latest News

ACIP Votes in Favor of Heplisav-B for Hepatitis B Prevention in Adults

ACIP Votes in Favor of Heplisav-B for Hepatitis B Prevention in Adults

The FDA approval of Heplisav-B was based on data from 3 phase 3 noninferiority trials involving close to 10,000 adults who received the vaccine.

Hepatitis C Virus Treatments

Hepatitis C Virus Infection dose chart with characteristics of patients for whom therapy is widely accepted.

Case of Psoriasis Remission After Hepatitis C Treatment

Case of Psoriasis Remission After Hepatitis C Treatment

A case of remission of psoriasis after treatment of chronic hepatitis C virus has been described.

Shorter duration of glecaprevir-pibrentasvir effective against hepatitis C virus: The ENDURANCE trials

Both 8 and 12-week regimens of glecaprevir-pibrentasvir were highly efficacious in producing sustained virologic response in patients infected with hepatitis C virus genotypes 1 and 3, and the 8-week treatment duration was noninferior to 12-week duration.

ACIP Issues Updated Recommendations for Preventing HBV Infection

ACIP Issues Updated Recommendations for Preventing HBV Infection

The Advisory Committee on Immunization Practices has issued updated recommendations for HBV prevention.

New Two-Dose Hepatitis B Vaccine for Adults Now Available

New Two-Dose Hepatitis B Vaccine for Adults Now Available

Dynavax Technologies announced the availability of a two-dose hepatitis B vaccine for adults.

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Reduced DAA delays and denials for patients with HCV reduced with provider-pharmacy collaboration.

Hepatitis B Vaccination Prevalence Low in Patients With HIV

Hepatitis B Vaccination Prevalence Low in Patients With HIV

More than one-third of adult US HIV patients miss opportunities to initiate hepatitis B vaccination.

Statewide Increase in Hepatitis C Virus Vertical Transmission Found

Statewide Increase in Hepatitis C Virus Vertical Transmission Found

State medical surveillance data suggest that the risk for mother-to-infant vertical transmission of hepatitis C virus is increasing.

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin demonstrated high rates of adherence and SVR in different HCV patient subgroups, including patients with advanced fibrosis combined with chronic comorbidities.

Sign Up for Free e-newsletters